Skip to main content
Year archive

Xlife Sciences AG — 2023 filings

All 48 regulatory filings released by Xlife Sciences AG (XLS) in 2023, sourced directly from the official regulator.

48 Filings
2023 Period
2023 filings (48)
Filing Released Lang
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
M&A Activity
2023-12-29 English
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
M&A Activity
2023-12-29 English
VERAXA Biotech AG übernimmt Synimmune GmbH zur Erweiterung des Krebsportfolios
Regulatory Filings
2023-12-29 German
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
Report Publication Announcement
2023-12-22 English
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
Regulatory Filings
2023-12-22 English
Xlife Sciences AG erreicht bedeutenden Meilenstein in der Entwicklung von Radiodiagnostika für Lebererkrankungen
Regulatory Filings
2023-12-22 German
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
M&A Activity
2023-12-20 English
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
Regulatory Filings
2023-12-20 English
Xlife Sciences AG ebnet Weg für nächste erfolgreiche Auslizenzierung und verkündet Kooperation mit Quant Biomarkers AG zur Entwicklung fortgeschrittener Biomarker für Nierenerkrankungen
Regulatory Filings
2023-12-20 German
Revolutionary AI Algorithm Prostate.Carcinoma.ai Achieves EU MDR Class IIa Registration
Report Publication Announcement
2023-12-18 English
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration
Legal Proceedings Report
2023-12-18 English
Revolutionärer KI-Algorithmus «Prostate.Carcinoma.ai» erhält EU MDR Klasse IIa Zulassung
Regulatory Filings
2023-12-18 German
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
M&A Activity
2023-10-18 English
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
M&A Activity
2023-10-18 English
Erfolgreicher Exit eines Portfolio-Unternehmens und bedeutende Investition in KI und digitale Gesundheit bei der Früherkennung von Krebs im Wert von CHF 23.3 Mio.
Investor Presentation
2023-10-18 German
ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023
Environmental & Social Information
2023-09-29 English
ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023
Environmental & Social Information
2023-09-29 English
ESG-Bericht zeigt Status Quo und skizziert den Weg für zukünftige Nachhaltigkeits-Verbesserungen Medienmitteilung Zürich, 29. September 2023
Environmental & Social Information
2023-09-29 German
Xlife Sciences with significant progress in H1 2023
Earnings Release H1 2023
2023-09-21 English
Xlife Sciences with significant progress in H1 2023
Earnings Release H1 2023
2023-09-21 English
Xlife Sciences mit signifikanten Fortschritten im 1. Halbjahr 2023
Earnings Release H1 2023
2023-09-21 German
Collaboration of Xlife Sciences and the Department of Health Abu Dhabi to drive global innovations in the life sciences sector
Regulatory Filings
2023-08-17 English
Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector
Regulatory Filings
2023-08-17 English
Kooperation der Xlife Sciences AG und dem Department of Health - Abu Dhabi zur Förderung globaler Innovationen im Bereich der Life Sciences
Regulatory Filings
2023-08-17 German
Media Release Zurich, June 20, 2023 Xlife Sciences: shareholders approved all motions at todays AGM 2023
AGM Information
2023-06-20 English
Media Release Zurich, June 20, 2023   Xlife Sciences: shareholders approved all motions at today’s AGM 2023
AGM Information
2023-06-20 English
Medienmitteilung Zürich, 20. Juni 2023   Xlife Sciences: Aktionärinnen und Aktionäre stimmten allen Anträgen an der heutigen Generalversammlung 2023 zu
AGM Information
2023-06-20 German
Xlife Sciences publishes agenda for Annual General Meeting 2023
AGM Information
2023-05-26 English
Xlife Sciences publishes agenda for Annual General Meeting 2023
AGM Information
2023-05-26 English
Xlife Sciences veröffentlicht Traktanden der Generalversammlung 2023
AGM Information
2023-05-26 German
Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential
Report Publication Announcement
2023-04-27 English
Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential
Net Asset Value
2023-04-27 English
Xlife Sciences: Valuation Report 2022 bestätigt und unterstreicht langfristiges Portfolio-Potenzial
Earnings Release FY 2022
2023-04-27 German
Xlife Sciences publishes 2022 results and 2023 outlook
Earnings Release FY 2022
2023-04-20 English
Xlife Sciences publishes 2022 results and 2023 outlook
Earnings Release FY 2022
2023-04-20 English
Xlife Sciences veröffentlicht Ergebnisse 2022 und Ausblick 2023
Earnings Release FY 2022
2023-04-20 German
saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
Regulatory Filings
2023-02-16 English
saniva diagnostics receives approval from the US FDA for its medical product NeuroMex
Regulatory Filings
2023-02-16 English
saniva diagnostics erhält Genehmigung der US-Gesundheitsbehörde FDA für ihr Medizinprodukt NeuroMex
Regulatory Filings
2023-02-16 German
Stifel initiates research coverage of Xlife Sciences
Report Publication Announcement
2023-01-23 English
Stifel initiates research coverage of Xlife Sciences
Report Publication Announcement
2023-01-23 English
Aufnahme der Research-Abdeckung von Xlife Sciences durch Stifel
Report Publication Announcement
2023-01-23 German
Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle
Environmental & Social Information
2023-01-20 English
Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle
Regulatory Filings
2023-01-20 English
Xlife Sciences: Schweizer Portfoliogesellschaft Axenoll erhält strategisch bedeutsames Patent des Europäischen Patentamts
Regulatory Filings
2023-01-20 German
Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)
Regulatory Filings
2023-01-16 English
Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)
Regulatory Filings
2023-01-16 English
Xlife Sciences-Portfoliogesellschaft startet Projekt zur Erforschung einer potenziellen Therapie gegen Amyotrophe Lateralsklerose (ALS)
Regulatory Filings
2023-01-16 German